Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?

Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S.

Gynecol Oncol. 2018 Aug;150(2):253-260. doi: 10.1016/j.ygyno.2018.05.025. Epub 2018 Jun 5.

PMID:
29884437
2.

Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.

Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP.

Eur J Cancer. 2018 Jul;98:30-37. doi: 10.1016/j.ejca.2018.03.004. Epub 2018 May 31.

PMID:
29859339
3.

Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group.

Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L.

Ann Intern Med. 1989 Jul 1;111(1):22-7.

PMID:
2472080
4.

Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.

Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP; Pediatric Oncology Group 9049; Children's Cancer Group 8882.

J Clin Oncol. 2004 Jul 1;22(13):2691-700.

PMID:
15226336
5.

[BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].

Göbel U, Calaminus G, Teske C, Bamberg M, Bökkerink JP, Haas RJ, Holschneider AM, Janka-Schaub G, Jürgens H, Mittler U, et al.

Klin Padiatr. 1993 Jul-Aug;205(4):231-40. German.

PMID:
7690864
6.

Chemotherapy of ovarian germ cell tumors.

Williams SD.

Hematol Oncol Clin North Am. 1991 Dec;5(6):1261-9. Review.

PMID:
1663943
7.

Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.

Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.

Gynecol Oncol. 2015 Jun;137(3):418-22. doi: 10.1016/j.ygyno.2015.03.054. Epub 2015 Apr 1.

PMID:
25842162
8.

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.

Terenziani M, Bisogno G, Boldrini R, Cecchetto G, Conte M, Boschetti L, De Pasquale MD, Biasoni D, Inserra A, Siracusa F, Basso ME, De Leonardis F, Di Pinto D, Barretta F, Spreafico F, D'Angelo P.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26568. Epub 2017 Apr 27.

PMID:
28449306
9.

Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution.

Lee CW, Song MJ, Park ST, Ki EY, Lee SJ, Lee KH, Ryu KS, Park JS, Hur SY.

World J Surg Oncol. 2011 Oct 11;9:123. doi: 10.1186/1477-7819-9-123.

10.

[Ovarian malignant tumours. Efficacy of germ cell and sex cord tumour treatment protocol in Poland].

Popadiuk S, Korzon M, Chybicka A, Szmyd K, Dzierzega M, Trelińska J, Kowalczyk JR, Wiśniewska-Slusarz H, Woźniak W, Bilska K, Wachowiak J, Konatkowska B, Wysocki M, Krawczuk-Rybak M, Czauderna P, Szumera M, Sznurkowska K, Renke J.

Med Wieku Rozwoj. 2006 Jul-Sep;10(3 Pt 1):803-10. Polish.

PMID:
17317911
11.

Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.

Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK.

Gynecol Oncol. 2004 Dec;95(3):496-9.

PMID:
15581952
12.

Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant Pau.

Germá JR, Izquierdo MA, Seguí MA, Climent MA, Ojeda B, Alonso C.

Gynecol Oncol. 1992 May;45(2):153-9.

PMID:
1375576
13.
14.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group.

Br J Cancer. 2005 Nov 28;93(11):1209-14.

15.

Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.

Duhil de Bénazé G, Pacquement H, Faure-Conter C, Patte C, Orbach D, Corradini N, Berger C, Sudour-Bonnange H, Vérité C, Martelli H, Fresneau B.

Eur J Cancer. 2018 Mar;91:30-37. doi: 10.1016/j.ejca.2017.11.030. Epub 2018 Jan 11.

PMID:
29331749
16.

Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group.

Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL.

J Clin Oncol. 2014 Feb 10;32(5):465-70. doi: 10.1200/JCO.2013.51.1006. Epub 2014 Jan 6.

17.

Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009).

Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD.

Gynecol Oncol. 2013 Nov;131(2):330-5. doi: 10.1016/j.ygyno.2013.08.028. Epub 2013 Aug 31.

PMID:
24001518
18.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

19.

[Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].

Sun XF, Yang QY, Zhen ZJ, Xia Y, Huang ZH, Ling JY.

Ai Zheng. 2006 Dec;25(12):1529-32. Chinese.

PMID:
17166380
20.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Oct;26(10):2125-32. doi: 10.1093/annonc/mdv310. Epub 2015 Jul 21. Erratum in: Ann Oncol. 2015 Dec;26(12):2507-8.

Supplemental Content

Support Center